The Less Survivable Cancers Taskforce (LSCT) welcomes the announcement of the reformed National Cancer Board and its new co-chairs Anita Charlesworth and Mark Cubbon. Read more below 👇 lnkd.in/e8B7CkhG

The Less Survivable Cancers Taskforce (LSCT) welcomes the appointment of Dr Sara Stoneham as the National Institute for Health and Care Research’s new Specialty Lead for Rare Cancers. Read more below 👇 lesssurvivablecancers.org.uk…

Yesterday, the APPG on Less Survivable Cancers met to discuss how to drive innovation in treating rare cancers. We're grateful to Minister @SharonHodgsonMP for joining to hear our thoughts and to @JoshFG MP for chairing.

Two fantastic charities have joined our coalition to improve outcomes for those with less survivable cancers (LSCs). Brain Tumour Research @braintumourrsch focuses on finding a cure for all brain tumours and Tenovus Cancer Care @tenovuscancer works in Wales on three three LSCs.

APPG on Less Survivable Cancers met re. the Rare Cancers Act's National Lead for Rare Cancers and what they will need for success. We will write to ministers with our recommendations. Next meeting, re. orphan drugs, in July. Thank you to our chair @PauletteHamilto

We ask the next Welsh Government to take urgent action and commit to a specific focus on improving outcomes and doubling survival rates for the less survivable cancers.

We’re calling on the next Scottish Government to close the deadly cancer gap. Less survivable cancers account for 1 in 4 diagnoses in Scotland, but average 5-year survival is just 16%. It’s time to improve outcomes, address research gaps and prioritise early diagnosis for LSCs.

The Rare Cancers Act 2026 received Royal Assent on Friday - a major milestone for people affected by less survivable cancers. The Taskforce will continue working with government and partners across the UK to ensure this Act delivers real change.

Following the AGM, the APPG on Less Survivable Cancers held a spotlight session on treatment delays, exploring the systemic barriers patients face in accessing timely treatment, as well as the changes needed to improve access and outcomes.